Press Release
November 4, 2021
Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today that updated results from the company’s ongoing ADVANCE II study with Immunicum’s cancer relapse vaccine DCP-001 will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021.
The ADVANCE II study is an international, multi-center, open label Phase II study in which two different dosing regimens of DCP-001 are studied in acute myeloid leukemia patients with persistent measurable residual disease (MRD).
“Initial results from the ADVANCE II study reported to date demonstrated that treatment with DCP-001 was safe, well tolerated and showed promising early signs of efficacy on converting patients to an MRD negative status,” commented Jeroen Rovers, M.D., Ph.D., Chief Medical Officer at Immunicum. “We look forward to sharing more mature data from the fully enrolled clinical study with the scientific and medical community at the ASH conference this year.”
Accepted abstracts will be available online on the ASH website on November 4th from 9:00 AM Eastern Daylight Time (EDT) 2:00 PM Central European Time (CET): https://www.hematology.org/meetings/annual-meeting/abstracts
Poster Details:
Poster Title: Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival
Presenter: Arjan Van de Loosdrecht, Ph.D,
Abstract Number: 1274
Session Title: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
Session Date & Time: Saturday, December 11, 2021, 5:30 PM - 7:30 PM EST
Location: Georgia World Congress Center, Hall B5
All posters will be made available as virtual ePosters throughout the 63rd ASH Annual Meeting. In addition, the poster will be made available on the Immunicum website following the poster presentation.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Brendan Payne
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com
For Sweden:
Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
MEDIA RELATIONS
Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu
About Immunicum AB (publ)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com
Attachment
